Impax Asset Management Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,587	Closed	-$495K	–	309
2023 Q4	$495K	Sell	2,587 -316	-11%	-$53.8K	﹤0.01%	340
2023 Q3	$514K	Sell	2,903 -165	-5%	-$31.5K	﹤0.01%	330
2023 Q2	$583K	Buy	3,068 +48	+2%	+$9.52K	﹤0.01%	327
2023 Q1	$605K	Buy	3,020 +312	+12%	+$65.6K	﹤0.01%	308
2022 Q4	$644K	Sell	2,708 -954	-26%	-$203K	﹤0.01%	298
2022 Q3	$733K	Buy	3,662 +350	+11%	+$66.8K	﹤0.01%	290
2022 Q2	$483K	Sell	3,312 -786	-19%	-$112K	﹤0.01%	325
2022 Q1	$669K	Buy	4,098 +307	+8%	+$46.8K	﹤0.01%	322
2021 Q4	$642K	Sell	3,791 -12,521	-77%	-$2.33M	﹤0.01%	332
2021 Q3	$3.08M	Buy	16,312 +66	+0.4%	+$12.4K	0.01%	220
2021 Q2	$2.75M	Buy	16,246 +1	+0%	+$146	0.01%	226
2021 Q1	$2.29M	Buy	16,245 +110	+0.7%	+$16.6K	0.01%	234
2020 Q4	$2.1M	Sell	16,135 -35,031	-68%	-$4.68M	0.01%	201
2020 Q3	$7.45M	Buy	51,166 +21,074	+70%	+$2.99M	0.07%	129
2020 Q2	$4.46M	Buy	30,092 +8,754	+41%	+$1.18M	0.05%	160
2020 Q1	$2.32M	Buy	21,338 +18,879	+768%	+$2.18M	0.03%	187
2019 Q4	$283K	Buy	+2,459	New	+$245K	﹤0.01%	263